Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cone-rod dystrophy in which the cause of the disease is a mutation in the RAB28 gene.
Features include always present findings: Reduced visual acuity, High myopia, and Cone/cone-rod dystrophy; and common findings: Foveal hyperpigmentation and Central scotoma. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 1 | Foveal atrophy |
RAB28 function has not been fully characterized.
Cone-rod dystrophy 18 is associated with mutations in the RAB28 gene on chromosome 4.
Genetic testing for RAB28 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cone-rod dystrophy 18 has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 2 common features.
No clinical trials have been registered for cone-rod dystrophy 18.
33 publications have been identified in PubMed for cone-rod dystrophy 18. Research spans Epidemiology / Natural History (42%), Case Report / Case Series (27%), and Review / Meta-Analysis (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 14 | 42% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:59 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about cone-rod dystrophy 18
1 |
Foveal hyperpigmentation |
9 |
27% |
Research summaries | 4 | 12% |
Testing and diagnosis research | 2 | 6% |
Laboratory research | 2 | 6% |
Other research | 1 | 3% |
New treatment approaches | 1 | 3% |
Mizobuchi K (2026). [PMID: 42102949](https://pubmed.ncbi.nlm.nih.gov/42102949/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Pagán-Melvin C (2026). [PMID: 41841063](https://pubmed.ncbi.nlm.nih.gov/41841063/). *Cureus*. [Case Report / Case Series]
Takács Á (2026). [PMID: 41595520](https://pubmed.ncbi.nlm.nih.gov/41595520/). *Genes (Basel)*. [Epidemiology / Natural History]
Varghese DE (2026). [PMID: 41846671](https://pubmed.ncbi.nlm.nih.gov/41846671/). *Cureus*. [Case Report / Case Series]
Mahler EA (2026). [PMID: 41238926](https://pubmed.ncbi.nlm.nih.gov/41238926/). *Ophthalmologie*. [Epidemiology / Natural History]
Zhou Y (2026). [PMID: 41933583](https://pubmed.ncbi.nlm.nih.gov/41933583/). *Ophthalmol Retina*. [Epidemiology / Natural History]
Hong Y (2026). [PMID: 41242591](https://pubmed.ncbi.nlm.nih.gov/41242591/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Frasson M (2026). [PMID: 42185784](https://pubmed.ncbi.nlm.nih.gov/42185784/). *Ophthalmic Genet*. [Case Report / Case Series]
Parekh BJ (2026). [PMID: 41760091](https://pubmed.ncbi.nlm.nih.gov/41760091/). *Clin Exp Ophthalmol*. [Epidemiology / Natural History]
Gregory-Evans CY (2026). [PMID: 41539649](https://pubmed.ncbi.nlm.nih.gov/41539649/). *Can J Ophthalmol*. [Epidemiology / Natural History]